Furthermore, TGs were lower in DHA-treated children than in controls at any time intervention, ALT was lower in groups with 12 months of DHA treatment onwards, and HOMA was lower in the group given 250 mg DHA/day versus placebo group at 6 and 12 months [64], in agreement with the positive outcomes reported in adult NAFLD patients. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.